LYNNTECH INC. — Department of Defense SBIR Phase I: A17-131

Description

This proposed SBIR effort specifically aims to develop a highly innovative new approach termed 3IN1 for the stabilization, preservation and concentration of disease markers within serum or urine samples for later serological diagnosis. 3IN1 could potentially enable bridging the existing challenges in the need for a cold chain for transportation of clinical specimens from the point-of-collection to a diagnostic laboratory, degradation and loss of analyte content during shipping and low abundance of certain biomolecular analytes of interest all of which could lead to false negative diagnoses. Moreover, the small size, low cost and user friendly features of 3IN1 would enable seamless integration into the existing sample processing workflow currently utilized for diagnosis. The proposed Phase I effort will focus on providing strong proof-of-concept for the 3IN1 approach. Future phases will focus on demonstration of clinical utility of 3IN1 to significantly aid in definitive and early diagnosis of the causative of febrile illness of infectious origin, obtaining FDA regulatory clearance and commercialization of 3IN1. The availability of 3IN1 could have a significant and positive impact at all levels of military medical care by enabling more reliable diagnosis and thereby guiding definitive treatment resulting in faster return to duty.